IPP Bureau
CARE Hospitals hosts insurance summit to strengthen trust in healthcare
By IPP Bureau - December 22, 2025
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Care ADHD opens its first Global Capability Centre in India
By IPP Bureau - December 22, 2025
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
By IPP Bureau - December 22, 2025
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Ipsen’s FALKON trial falls short in rare FOP study, offers key insights
By IPP Bureau - December 22, 2025
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Xeureka & UBE launch joint cancer drug discovery program
By IPP Bureau - December 22, 2025
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Sai Life Sciences unveils 2024–25 sustainability report
By IPP Bureau - December 22, 2025
The company also reported significant progress toward its internally defined Sustainable Development Goals
MARAbio launches first blood test to detect maternal autoantibody-linked autism
By IPP Bureau - December 22, 2025
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Abbott wins FDA & CE nod for groundbreaking premature infant heart device
By IPP Bureau - December 22, 2025
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
UK to get groundbreaking early detection test for bowel cancer
By IPP Bureau - December 22, 2025
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access
By IPP Bureau - December 22, 2025
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Emcure Pharma launches weight loss drug Poviztra in India
By IPP Bureau - December 22, 2025
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
CORONA Remedies commissions additional capacity
By IPP Bureau - December 22, 2025
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
KIMS inks land agreement with Andhra Mahila Sabha to set up Rs. 300 crore hospital in Chennai
By IPP Bureau - December 22, 2025
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Granules receives FDA tentative approval for generic Amphetamine ER orally disintegrating tablets
By IPP Bureau - December 22, 2025
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million
By IPP Bureau - December 22, 2025
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
